2021 Clinical Neuromuscular Pathology Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2021 Clinical Neuromuscular Pathology reading list.

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

• Recognize different distal myopathies and identify the testing needed to identify them
• Recognize clinical and serological features that are associated with the pathological finding of vasculitis
• Recognize pathological findings that help separate CIDP from POEMS syndrome and from multifocal motor neuropathy

Core Competencies

• Medical Knowledge

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within three weeks of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1^TM credit(s). Physicians should claim only their credit commensurate with the extent of the participation in the activity.

ABPN Self-Assessment Designation Statement

The American Board of Psychiatry & Neurology (ABPN) has reviewed the UCNS Continuous Certification (C-cert) self-assessment activity and has approved the program as a part of a comprehensive self-assessment (SA) program, which is mandates by the American Board of Medical Specialties as a necessary component of maintenance of certification. The number of ABPN SA credits granted will equal the number of CME hours claimed for the activity. 

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy. 

2021 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

P. James B. Dyck, MD, FAAN, Chair, Mayo Clinic – Rochester 
Disclosures: Receives fees from Akcea pharmaceutical for speaking about TTR amyloid neuropathy.

Andrea M. Corse, MD, Vice Chair, Johns Hopkins Hospital
Disclosures: Received research funding from Biogen to present A Phase I, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis.

Robert C. Bucelli, MD, PhD, Washington University School of Medicine
Disclosures: Receives research support from Biogen for multiple ALS ASO trials at Washington University. Role: Principal investigator.

Mazen Mohammad Dimachkie, MD, University of Kansas Medical Center
Disclosures: Serves as a paid consultant for ArgenX, Catalyst, CSL-Behring, Kezar, Momenta, NuFactor, RMS Medical, Sanofi Genzyme, Shire Takeda, and Spark Therapeutics; received research grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Sanofi Genzyme, Octapharma, Orphazyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed & TMA. 

Ahmed Mohamed Attia El-Dokla, MD, Neuromuscular Clinic at Upstate Bone & Joint
Disclosures: Nothing to disclose.

Shalini Mahajan, MD, Cedars-Sinai Medical Center
Disclosures: Nothing to disclose.

Raghav Govindarajan, MD, University of Missouri
Disclosures: Received compensation from Alexion MT PHARMA Catalyst PHARMA Argenx Infucare; received publication fees from Springer Publishing; research support received from Ra PHARMA Alexion Dysimmune foundation Band of Hope foundation.

Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Receives compensation for serving as associate editor of Neurology Genetics; Receives research funding by Mayo Clinic benefactor.

Michelle Lynn Mauermann, MD, Mayo Clinic – Rochester
Disclosures: Receives research support from Alnylam for TTR amyloid clinical trial and from IONIS for TTR amyloid clinical trial.

Aziz Shaibani, MD, Nerve and Muscle Center of Texas
Disclosures: Received compensation to serve on Stealth BioTherapeutics advisory board regarding primary mitochondrial myopathy (PMM) and elamipretide.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326